|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4245-4248.
Prepublished online as a Blood First Edition Paper on January 30, 2007; DOI 10.1182/blood-2006-08-039347.
 Previous Article | Table of Contents | Next Article 
HEMATOPOIESIS
Human bone marrow mesenchymal stromal cells express the neural ganglioside GD2: a novel surface marker for the identification of MSCs
Caridad Martinez1,
Ted J. Hofmann1,
Roberta Marino1,2,
Massimo Dominici3, and
Edwin M. Horwitz1
1 Division of Bone Marrow Transplantation, St Jude Children's Research Hospital, Memphis, TN;
2 Department of Pediatrics, Federal University of Sao Paulo, Brazil; and
3 Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
Mesenchymal stromal cells (MSCs) have enormous potential for the regeneration of bone, cartilage, and other tissues derived from primitive mesoderm. Despite extensive research, there is still no single marker that reliably identifies MSCs within the bone marrow. Using immunocytochemistry and flow cytometry, we demonstrate here that the neural ganglioside GD2 is expressed by MSCs either newly isolated from bone marrow or expanded in tissue culture; this finding was supported by reverse transcriptase–polymerase chain reaction (RT-PCR) analysis showing expression of the mRNA for GD2 synthase, an essential enzyme for GD2 biosynthesis. GD2 was also expressed on MSCs isolated from adipose tissue, but not on foreskin fibroblasts. Importantly, MSCs were the only cells within normal marrow that expressed this marker. Thus, GD2 appears to be the first reported single surface marker that uniquely distinguishes MSCs from other marrow elements. GD2 may prove valuable to study MSC biology and for the preparation of MSCs for clinical applications.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
V. L. Battula, S. Treml, P. M. Bareiss, F. Gieseke, H. Roelofs, P. de Zwart, I. Muller, B. Schewe, T. Skutella, W. E. Fibbe, et al.
Isolation of functionally distinct mesenchymal stem cell subsets using antibodies against CD56, CD271, and mesenchymal stem cell antigen-1
Haematologica,
February 1, 2009;
94(2):
173 - 184.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Haniffa, M. P. Collin, C. D. Buckley, and F. Dazzi
Mesenchymal stem cells: the fibroblasts' new clothes?
Haematologica,
February 1, 2009;
94(2):
258 - 263.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Lee, M. J. Seo, A. A. Pulin, C. A. Gregory, J. Ylostalo, and D. J. Prockop
The CD34-like protein PODXL and {alpha}6-integrin (CD49f) identify early progenitor MSCs with increased clonogenicity and migration to infarcted heart in mice
Blood,
January 22, 2009;
113(4):
816 - 826.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Stutterheim, A. Gerritsen, L. Zappeij-Kannegieter, I. Kleijn, R. Dee, L. Hooft, M. M. van Noesel, M. Bierings, F. Berthold, R. Versteeg, et al.
PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma
J. Clin. Oncol.,
November 20, 2008;
26(33):
5443 - 5449.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sessarego, A. Parodi, M. Podesta, F. Benvenuto, M. Mogni, V. Raviolo, M. Lituania, A. Kunkl, G. Ferlazzo, F. D. Bricarelli, et al.
Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application
Haematologica,
March 1, 2008;
93(3):
339 - 346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Delorme, J. Ringe, N. Gallay, Y. Le Vern, D. Kerboeuf, C. Jorgensen, P. Rosset, L. Sensebe, P. Layrolle, T. Haupl, et al.
Specific plasma membrane protein phenotype of culture-amplified and native human bone marrow mesenchymal stem cells
Blood,
March 1, 2008;
111(5):
2631 - 2635.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jones and D. McGonagle
Human bone marrow mesenchymal stem cells in vivo
Rheumatology,
February 1, 2008;
47(2):
126 - 131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
